FDA approves Gemtesa for overactive bladder in men with benign prostatic hyperplasia
Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...
Renal & Urology News4 天
Gemtesa Approved for Men With OAB Symptoms Receiving BPH Treatment
The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.
HealthDay on MSN18 小时
FDA Approves Gemtesa for Overactive Bladder in Men With BPH
Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) symptoms ...
Nature3 个月
Solifenacin causes less dry mouth than oxybutynin in OAB
Patients with chronic overactive bladder (OAB) are usually treated long-term with antimuscarinic agents. However, adherence to treatment is poor—rates as low as 20% at 1 year have been reported ...
Medscape5 天
Percutaneous Tibial Nerve Stimulation for the Treatment of Overactive Bladder
The standard treatments for overactive bladder include lifestyle changes, bladder training, pelvic floor muscle training and anticholinergic (anti-muscarinic) drugs. Additional treatments for some ...
The Pharma Letter10 天
Sumitomo gains FDA approval of Gemtesa for OAB
The US subsidiary of Japan’s Sumitomo Pharma announced that the US Food and Drug Administration (FDA) has approved Gemtesa ...
WebMD2 年
Incontinence & Overactive Bladder Resource Center
Some are minor, and some are more serious. What you eat and drink, as well as the drugs you take, may all have an effect on incontinence symptoms. If your symptoms are making your life difficult ...
Medscape1 个月
Percutaneous Tibial Nerve Stimulation for the Treatment of Overactive Bladder
The Urgent PC Modulation System first received FDA 510K marketing clearance (K052025) in 2005 for the treatment of urinary urgency, urinary frequency, and urge incontinence. The FDA considers the ...